We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
BioCryst Pharmaceuticals has announced that BCX-4208 has successfully completed
a Phase I, placebo-controlled, single ascending dose, pharmacokinetic and safety
trial involving 84 healthy volunteers.
Isis Pharmaceuticals has initiated a Phase I study of an oral capsule formulation
of ISIS 301012, a second-generation antisense inhibitor of apoB-100, for the
lowering of high cholesterol.
Generex Biotechnology, a leader in the area of buccal drug delivery, has reported
results of a recently completed Phase IIb clinical study of Oral-lyn in which
Oral-lyn successfully replaced rapid-acting insulin in patients with Type 1
diabetes mellitus.
Critical Therapeutics has initiated an open-label, Phase IIIb study of its investigational
drug, ZYFLO Filmtab, for patients with asthma who have previously benefited
from ZYFLO and require it to control their asthma.
Genentech and Roche have announced that an interim analysis of a Phase III study
of Avastin (bevacizumab) plus paclitaxel and carboplatin chemotherapies in first-line
non-squamous, non-small cell lung cancer (NSCLC) met its primary efficacy endpoint
of improving overall survival, or a reduction in the risk of death, compared
to chemotherapy alone.
The U.S. Patent and Trademark Office has awarded a patent to Genaissance Pharmaceuticals
for a method testing individuals for genetic predisposition to reduced metabolism
of drugs.
Tripos, a provider of drug discovery chemistry and informatics products
and services, has been awarded an $860,000 Phase II Small Business Innovation
Research grant from the NIH.
Medidata Solutions, a global electronic clinical data management solutions provider,
will provide Pro-Pharmaceuticals, a developer of novel carbohydrate compounds
that enable the targeted delivery of chemotherapy drugs to cancer cells, with
state-of-the-art electronic data capture technology for Pro-Pharmaceuticals'
Phase II clinical trial.
NexMed, a developer of innovative transdermal treatments based on its proprietary
NexACT drug delivery technology, has achieved 90 percent patient enrollment
in its U.S. Phase I clinical trial of NM100060, its proprietary lacquer treatment
of nail fungus (onychomycosis).
Axonyx has announced interim results from the first 37 patients in a Phase IIb
double-blind, placebo-controlled, clinical trial (designated AX-CL-06a) designed
to evaluate the effects of Phenserine tartrate on cerebrospinal fluid levels
of beta-amyloid (A(beta) 1- 42) and other biomarkers in mild-to-moderate Alzheimer's
disease (AD) patients.